Literature DB >> 26459088

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.

B M Scirica, E Braunwald, I Raz, M A Cavender, D A Morrow, P Jarolim, J A Udell, O Mosenzon, K Im, A A Umez-Eronini, P S Pollack, B Hirshberg, R Frederich, B S Lewis, D K McGuire, J Davidson, P G Steg, D L Bhatt.   

Abstract

Entities:  

Year:  2015        PMID： 26459088     DOI： 10.1161/CIR.0000000000000330

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  23 in total

1.  Need for Outcome Scenario Analysis of Clinical Trials in Diabetes.

Authors:  Rosa Garcia-Verdugo; Michael Erbach; Oliver Schnell
Journal:  J Diabetes Sci Technol       Date:  2016-10-05

Review 2.  Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.

Authors:  Stephen J Greene; Muthiah Vaduganathan; Muhammad Shahzeb Khan; George L Bakris; Matthew R Weir; Jonathan H Seltzer; Naveed Sattar; Darren K McGuire; James L Januzzi; Norman Stockbridge; Javed Butler
Journal:  J Am Coll Cardiol       Date:  2018-03-10       Impact factor: 24.094

Review 3.  Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.

Authors:  Eberhard Standl; Oliver Schnell; Darren K McGuire
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

Review 4.  Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

Review 5.  DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.

Authors:  Chang Xia; Aditya Goud; Jason D'Souza; CHanukya Dahagam; Xiaoquan Rao; Sanjay Rajagopalan; Jixin Zhong
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

6.  Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease.

Authors:  Kenneth S Hershon; Barbara R Hirsch; Ola Odugbesan
Journal:  Clin Diabetes       Date:  2019-07

Review 7.  Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials.

Authors:  John R Ussher; Amanda A Greenwell; My-Anh Nguyen; Erin E Mulvihill
Journal:  Diabetes       Date:  2022-02-01       Impact factor: 9.461

8.  Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.

Authors:  Takayoshi Kanie; Atsushi Mizuno; Yoshimitsu Takaoka; Takahiro Suzuki; Daisuke Yoneoka; Yuri Nishikawa; Wilson Wai San Tam; Jakub Morze; Andrzej Rynkiewicz; Yiqiao Xin; Olivia Wu; Rui Providencia; Joey Sw Kwong
Journal:  Cochrane Database Syst Rev       Date:  2021-10-25

9.  SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.

Authors:  Rhanderson Cardoso; Fabrissio P Graffunder; Caique M P Ternes; Amanda Fernandes; Ana V Rocha; Gilson Fernandes; Deepak L Bhatt
Journal:  EClinicalMedicine       Date:  2021-06-05

Review 10.  Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities.

Authors:  Izabela Tuleta; Nikolaos G Frangogiannis
Journal:  Adv Drug Deliv Rev       Date:  2021-07-29       Impact factor: 17.873
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.